Fig. 7: Immune scores of published immune cells gene signatures. | Nature Communications

Fig. 7: Immune scores of published immune cells gene signatures.

From: Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial

Fig. 7

Comparison of immune scores of published immune cells gene signatures between pre- and post-neoadjuvant therapy (a) (n = 19) and across mRECIST response categories (b) SD (n = 7): stable disease, PR (n = 9): partial response, and CR (n = 3): complete response; blue represents patients at pre-neoadjuvant therapy and red represents patients at post-neoadjuvant therapy. Points show the log2 transformed immune scores for each patient. Boxplot accompanied with jittered points illustrates the distribution of log2 transformed immune scores for each patient. Within the box, horizontal line represents median, and box represents 25th and 75th percentile. Whiskers are calculated with the formula median ± 1.5 × interquartile range. Paired t-tests are conducted between pre- and post-treatment data, whereas pairwise comparisons across different mRECIST categories are assessed using the Wilcoxon rank-sum method. Exact two-sided p values, with significance levels (p value < 0.05), are provided above the respective comparisons. Source data are provided as a Source Data file.

Back to article page